GlassScriptPhysician profile
Douglas M Taylor
NPI 1518915693
$3,017.59
in general payments reported to CMS, 2019-2025
13 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $56.79 · 2021: $177 · 2022: $576 · 2023: $459 · 2024: $619 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $884.02 | 2019-2025 | Collagenase Santyl, Stravix, Grafix Pl |
| Bioventus LLC | $586.11 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Organogenesis INC. | $415.16 | 2019-2022 | |
| Orthofix Medical, INC. | $198.36 | 2022-2023 | Physio-Stim |
| Zimmer Biomet Holdings, INC. | $179.07 | 2020-2022 | |
| Kerecis Limited | $178.94 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Treace Medical Concepts, INC. | $163.92 | 2023-2025 | |
| Musculoskeletal Transplant Foundation INC. | $140.44 | 2021-2023 | |
| Bone Support INC. | $111.24 | 2024 | Ceramentbone Void Filler, Cerament G |
| Crossroads Extremity Systems, LLC | $92.05 | 2019 | |
| Sandoz INC. | $40.71 | 2019 | |
| Integra Lifesciences Corporation | $19.92 | 2020 | |
| Forte Bio-Pharma LLC | $7.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.